CAS: 385-02-4; 2-Fluoro-6-Nitrobenzoic Acid

上下游产品

1-fluoro-2-methyl-3-nitrobenzene (2-fluoro-6-nitrophenyl)methanol nitric acid 3-nitro-o-tolylamine 2-fluoro-6-nitrobenzoyl chloride methyl 2-fluoro-3-nitrobenzoate N-(5-chloropyridin-2-yl)-6-fluoro-2-nitrobenzamide

2-氨基-6-氟苯甲酸置于碳酸氢钠,Sodium Hydroxide,Oxone,乙二胺四乙酸体系中,用 水,丙酮 用作溶剂,化学反应 6.25H,以95%的收率获得2-氟-6-硝基苯甲酸
参考文献:发现新型的像toll样受体7和8的小分子双重抑制剂.
标题:发现新型的像toll样受体7和8的小分子双重抑制剂.
摘要:内体通行费样受体(tlr)7和8识别病毒单链rna,一类咪唑并喹啉化合物,8-氧代腺苷,8-氨基苯并二氮杂卓,嘧啶和鸟苷类似物.目前有大量证据表明,Tlr7特异性介导的慢性炎症与自身免疫进程有关.基于我们先前针对tlr8的筛选,我们确定了一种新的tlr7 / 8双重抑制剂(1)和tlr8特异性抑制剂(2).发现带有苯甲酰苯胺支架的化合物1在低微摩尔浓度下抑制tlr7和tlr8.我们设想对1的苯甲酰苯胺支架进行修改产生一类高度特异性的tlr7抑制剂.我们的努力导致发现了新的tlr8抑制剂(cu-115),并鉴定了带有独特的二苯醚骨架的tlr7 / 8双重抑制剂(cu-72),具有优化tlr7选择性的潜力.鉴于tlr8在自身免疫中的作用,我们还优化了2的效价并开发了带有1,3,4-恶二唑基序的新型tlr8抑制剂.
Doi:10.1021/acs.Jmedchem.9B01201

专利信息

专利号:US-8946410-B2
优先权日:2009-10-08
标 题 :Automated radiosynthesis
发明人：WOODCRAFT JOHN; JONES L CLARE; GAETA ALESSANDRA; TRIGG JOHN WILLIAM; JONES ALEXANDER PAUL; PLANT STUART; JACKSON ALEXANDER
权利人:WOODCRAFT JOHN; JONES L CLARE; GAETA ALESSANDRA; TRIGG JOHN WILLIAM; JONES ALEXANDER PAUL; PLANT STUART; JACKSON ALEXANDER; GE HEALTHCARE LTD
摘要:The present invention provides a method to obtain radiofluorinated compounds useful for in vivo imaging GABA A receptors. The method of the invention is high-yielding and may conveniently be carried out on an automated synthesizer such as Fastlabâ„¢. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention. Novel precursor compounds useful in the method of the invention are also provided, as are a number of novel compounds obtained by the method of the invention.

专利号:US-9096624-B2
优先权日:2009-06-01
标 题:Amino pyrimidine anticancer compounds
发明人：CREW ANDREW P; SHERMAN DAN; APPARI RAMA DEVI; CHEN XIN; CHILUKURI RAMESH; DONG HANQING; FERRARO CATERINA; FOREMAN KENNETH; GUPTA RAMESH C; LI AN-HU; STOLZ KATHRYN M; VOLK BRIAN; ZAHLER ROBERT
权利人:OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula 1, as shown below and defined herein: n n n n n n n n n n n n and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.